HealthEquity (HQY) Set to Announce Quarterly Earnings on Monday

HealthEquity (NASDAQ:HQY) is scheduled to post its quarterly earnings results after the market closes on Monday, December 9th. Analysts expect HealthEquity to post earnings of $0.71 per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.

HealthEquity (NASDAQ:HQY) last released its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.50 by $0.16. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. The business had revenue of $299.93 million for the quarter, compared to the consensus estimate of $284.48 million. On average, analysts expect HealthEquity to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.

HealthEquity Price Performance

Shares of NASDAQ:HQY opened at $100.21 on Friday. The firm has a market capitalization of $8.75 billion, a PE ratio of 83.51, a PEG ratio of 1.59 and a beta of 0.55. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51. HealthEquity has a 1-year low of $62.10 and a 1-year high of $105.82. The business’s 50 day moving average is $92.42 and its 200-day moving average is $83.58.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a report on Wednesday, September 4th. The Goldman Sachs Group initiated coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 target price on the stock. Bank of America raised their price target on shares of HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. Barrington Research increased their target price on HealthEquity from $105.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, December 2nd. Finally, Deutsche Bank Aktiengesellschaft boosted their price target on HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. One investment analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $109.64.

Insiders Place Their Bets

In related news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now directly owns 54,719 shares in the company, valued at $4,540,582.62. This represents a 13.10 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Frank Corvino sold 1,247 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total value of $100,084.22. Following the completion of the transaction, the director now directly owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 10,536 shares of company stock valued at $884,517. Insiders own 2.20% of the company’s stock.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.